ArticleLipids in health and disease2025
Remnant cholesterol, low-density lipoprotein cholesterol and atherosclerotic cardiovascular disease in metabolic dysfunction-associated steatotic liver disease: a cohort study.
Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exercise Versus Standard Therapy in Steatotic Liver Disease Spectrum: A Systematic Review, Meta-Analysis, and Meta-Regression.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundRecent studies highlighted the independent role of remnant cholesterol (RC) on the risk of atherosclerotic cardiovascular disease (ASCVD). We explored interrelationships among low-density lipoprotein cholesterol (LDL-C), RC, and ASCVD in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD).
methodsAnalyzing 25,418 MASLD and 57,501 non-MASLD ASCVD- free Chinese adults from the Kailuan Study (2006-2011), we used Fine-Gray models to evaluate LDL-C and RC associations with ASCVD across varying cut-offs, incorporating China-PAR (Prediction for Atherosclerotic Cardiovascular Disease Risk in China) 10-year risk.
resultsThe MASLD group had comparable LDL-C but elevated RC levels compared to the non-MASLD. In MASLD individuals, associations of LDL-C (J-shaped) and RC (linear) with ASCVD were observed, contrasting with the monotonically increasing relationships in non-MASLD individuals. Even with guideline-recommended LDL-C levels, the MASLD group with elevated RC alone showed a higher ASCVD risk. Among individuals with low ASCVD risk evaluated by the China-PAR model, MASLD patients with LDL-C < 1.8 mmol/L and RC < 0.6 mmol/L had comparable ASCVD risk to the non-MASLD group with LDL-C < 3.4 mmol/L and RC < 0.6 mmol/L (hazard ratio [HR]: 1.17; 95% confidence interval [CI]: 0.55-2.47). For those with moderate to high predicted ASCVD risk, the MASLD with the same lipid levels (LDL-C < 1.8 mmol/L and RC < 0.6 mmol/L) had a similar risk of ASCVD to that of the non-MASLD with LDL-C < 2.6 mmol/L and RC < 0.6 mmol/L (HR: 1.15; 95% CI: 0.71-1.86).
conclusionsThe findings indicate that MASLD alters the relationship between lipids and ASCVD, underscoring the necessity for integrated and stricter management of both LDL-C and RC to mitigate risk in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.